Substance / Medication

Ganciclovir

Overview

Active Ingredient
ganciclovir
RxNorm CUI
4678

Indications

ZIRGAN is indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in adults and pediatric patients aged 2 years and older.

Labeler: Bausch & Lomb IncorporatedUpdated: 2026-02-05T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Ganciclovir as a potential treatment for glioma: a systematic review and meta-analysis.
Chang Chun-Tao, Chen Hsing-Hui, Chuang Chun-Chao et al. · J Neurooncol · 2023
PMID: 38066255Meta-Analysis
The Effect of (Val)ganciclovir on Hearing in Congenital Cytomegalovirus: A Systematic Review.
De Cuyper Elise, Acke Frederic, Keymeulen Annelies et al. · Laryngoscope · 2022
PMID: 35072277Meta-Analysis
A systematic overview of the spermatotoxic and genotoxic effects of methotrexate, ganciclovir and mycophenolate mofetil.
Jensen Nicolai B, Justesen Signe D, Larsen Agnete et al. · Acta Obstet Gynecol Scand · 2021
PMID: 33755191Meta-Analysis
Systematic review of ganciclovir pharmacodynamics during the prevention of cytomegalovirus infection in adult solid organ transplant recipients.
Wong Diana D, van Zuylen Wendy J, Craig Maria E et al. · Rev Med Virol · 2019
PMID: 30556615Meta-Analysis
Intrauterine therapy of cytomegalovirus infection with valganciclovir: review of the literature.
Seidel Vera, Feiterna-Sperling Cornelia, Siedentopf Jan-Peter et al. · Med Microbiol Immunol · 2017
PMID: 28733760Meta-Analysis
[Clinical efficacy and safety of prolonged use of the valganciclovir for the treatment of cytomegalovirus disease in patients after kidney transplantation].
Kawalec Paweł, Szkultecka-Debek Monika, Maks Justyna et al. · Pol Merkur Lekarski · 2013
PMID: 23984598Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Ganciclovir (substance)
SNOMED CT
372848001
UMLS CUI
C0017066
RxNorm CUI
4678
Labeler
Bausch & Lomb Incorporated

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.